The U.S. Securities and Exchange Commission (SEC) has received an S-1 form from Tabula Rasa HealthCare regarding its initial public offering (IPO). No pricing details were given in the filing but the offering is valued up to $115 million. The company intends to list on the Nasdaq Global Market TRHC.

The underwriters for this offering are Wells Fargo, UBS Investment Bank, Piper Jaffray, Baird and Stifel.

This company is a leader in providing patient-specific, data-driven technology and solutions that enable health care organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower health care costs and manage risk.

Tabula Rasa delivers its solutions through a comprehensive suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs. It also provides risk adjustment services, which help clients to properly characterize a patient’s acuity, or severity of health condition, and optimize the associated payments for care.

In the filing, the company detailed:

With 4.3 billion prescriptions filled in the United States in 2014, medication treatment is the most common medical intervention, and its imprecise use represents the fourth leading cause of death and contributes to an estimated 45 to 50 million adverse drug events, or ADEs, annually with 2.5 to 4.0 million of those ADEs considered serious, disabling or fatal. ADEs result in more than 100,000 deaths annually in the United States and approximately 125,000 hospitalizations, one million emergency room visits, two million affected hospital stays and 3.5 million physician office visits every year. The incidence of ADEs is highly correlated to the number of medications an individual is taking and non-adherence to prescribed regimens, and thus is particularly relevant to populations with complex healthcare needs. Our technology-driven approach to medication risk management represents an evolution from prevailing non-personalized approaches that primarily rely on single drug-to-drug interaction analysis.

The company currently serves roughly 100 health care organizations that focus on populations with complex health care needs and extensive medication requirements.

The net proceeds from the offering are intended to be used to:

• Repay indebtedness
• Continue to develop new product offerings
• Enter into new market segments with existing solutions
• Expand sales and marketing infrastructure
• Fund acquisitions of businesses and technologies

The remainder will be used for working capital and general corporate purposes.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.